Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057005 · ClinicalTrials.gov registry record · Phase 1
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
A Phase 1 study of Leukemia, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 2
- Study locations
NCT00057005 is a Phase 1 study of Leukemia that has completed, run by Baylor College of Medicine. The registered enrollment target is 6 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00057005, a Phase 1 study of Leukemia, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
Participants in this study have a hematologic malignancy which is a disorder in the bone marrow that affects the body's ability to create blood. Participants might benefit from receiving an allogeneic stem cell transplant (meaning the cells come from a donor). The participants donor is a family member. Stem cells are cells in the bone marrow and blood that can form a whole new blood system.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Mesna
- DRUG CAMPATH-1H
- DRUG Anti-CD45
- DRUG Ara-C
Study Locations (2)
Texas
- Texas Children's Hospital - Houston
- The Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057005
The ClinicalTrials.gov registry entry for NCT00057005 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (99% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00057005 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00057005 about?
NCT00057005 is a clinical study titled "Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation". Participants in this study have a hematologic malignancy which is a disorder in the bone marrow that affects the body's ability to create blood. Participants might benefit from receiving an allogeneic stem cell transplant (meaning the cells come from a donor). The participants donor is a family memb...
What is the current status of trial NCT00057005?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2003-02. Estimated completion is 2009-10.
What conditions does trial NCT00057005 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00057005?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), CAMPATH-1H (DRUG), Anti-CD45 (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00057005?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00057005 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.